Hexoprenaline
Sold as Ipradol
Every registration of this product has been cancelled.
4-[2-[6-[[2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol
Drag to rotate. Structure from PubChem CID 3609.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharmacare limited û woodmeadCancelled | Ipradol | 25 mcg/10 ml | F0051, K0061 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ipradol EACH 5 ML SYRUP CONTAINS HEXOPRENALINE HYDROCHLORIDE 0,125 MG | Not listed | F0051F/10.2/51 | Cancelled | Not determined | None |
| Ipradol infusion 25 mcg/10 ML EACH 10 ml CONTAINS HEXOPRENALINE SULPHATE 25 ug | 25 mcg/10 mlInfusion | K0061K/18.9/61 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Hexoprenaline
- when intended for the prevention or delay of labour and preparations thereof for injection. (S2, S3)
Consolidated Schedules 06 July 2026, lines 6580 to 6581
S3: Hexoprenaline
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 3706
S2: Hexoprenaline
- except when contained in respirator solutions; (S3) and
- except when intended for injection or for the prevention or delay of labour. (S4)
Consolidated Schedules 06 July 2026, lines 2075 to 2079
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.